ABBV vs JNJ
AbbVie Inc. and Johnson & Johnson, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ABBV | JNJ |
|---|---|---|
| Revenue | $61.2B | $94.2B |
| Net income | $4.2B | $26.8B |
| Gross margin | 70.2% | 67.9% |
| Net margin | 6.9% | 28.5% |
| Return on equity | 15367.3% | — |
| Diluted EPS | $2.36 | $11.03 |
| Dividend / share | $6.65 | $5.14 |
| Payout ratio | 275.8% | — |
| Free cash flow | $17.8B | $19.7B |
| Equity | $-3.3B | — |
| Net debt / equity | 16.49× | — |
| Current ratio | 0.67× | 1.03× |
| Revenue CAGR 5y | 6.0% | 2.7% |
| Profit CAGR 5y | −1.7% | 12.7% |
JNJ bills 1.5× the revenue of ABBV, and keeps more of each dollar of revenue as profit (28.5% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ABBV | JNJ |
|---|---|---|
| FY2025 | $61.2B | $94.2B |
| FY2024 | $56.3B | $88.8B |
| FY2023 | $54.3B | $85.2B |
| FY2022 | $58.1B | $80.0B |
| FY2021 | $56.2B | $78.7B |
| FY2020 | $45.8B | $82.6B |
| FY2019 | $33.3B | $82.1B |
| FY2018 | $32.8B | $81.6B |
| FY2017 | $28.2B | $76.5B |
| FY2016 | $25.6B | $71.9B |
Net income by year
Bottom line
| Fiscal year | ABBV | JNJ |
|---|---|---|
| FY2025 | $4.2B | $26.8B |
| FY2024 | $4.3B | $14.1B |
| FY2023 | $4.9B | $35.2B |
| FY2022 | $11.8B | $17.9B |
| FY2021 | $11.5B | $20.9B |
| FY2020 | $4.6B | $14.7B |
| FY2019 | $7.9B | $15.1B |
| FY2018 | $5.7B | $15.3B |
| FY2017 | $5.3B | $1.3B |
| FY2016 | $6.0B | $16.5B |
Advertisement
AdSense · Rectangle 336×280